ArticlePLoS medicine2005
Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
Article in PLoS medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Statistical design and analysis of controlled human malaria infection trials.Malaria journal · 2024Article
- Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models.Nature reviews. Immunology · 2020Review
- Estimating the basic reproduction number of a pathogen in a single host when only a single founder successfully infects.PloS one · 2020Article
- An accurate approximation for the expected site frequency spectrum in a Galton-Watson process under an infinite sites mutation model.Theoretical population biology · 2019Article
- Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV.PloS one · 2018Article
- Host Responses to Pathogen Priming in a Natural Songbird Host.EcoHealth · 2017Article
- Article
- Tackling HIV and AIDS: contributions by non-human primate models.Lab animal · 2017Article
- Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.PLoS pathogens · 2017Article
- Survivors Remorse: antibody-mediated protection against HIV-1.Immunological reviews · 2017Review
- Short Communication: Practical Experience with Analysis and Design of Repeat Low-Dose SHIVSF162P3 Exposure Studies in Female Pigtail Macaques with Varying Susceptibility During Menstrual Cycling.AIDS research and human retroviruses · 2015Article
- Parsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models.PLoS pathogens · 2015Article
- Repeated Low-Dose Influenza Virus Infection Causes Severe Disease in Mice: a Model for Vaccine Evaluation.Journal of virology · 2015Article
- Analysis of repeated low-dose challenge studies.Statistics in medicine · 2015Article
- Surrogates of protection in repeated low-dose challenge experiments.Statistics in medicine · 2015Article
- A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments.Biostatistics (Oxford, England) · 2015Article
- Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment.PloS one · 2015Article
- Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection.Nature medicine · 2014Article
- Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.The Journal of antimicrobial chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTrials in macaque models play an essential role in the evaluation of biomedical interventions that aim to prevent HIV infection, such as vaccines, microbicides, and systemic chemoprophylaxis. These trials are usually conducted with very high virus challenge doses that result in infection with certainty. However, these high challenge doses do not realistically reflect the low probability of HIV transmission in humans, and thus may rule out preventive interventions that could protect against "real life" exposures. The belief that experiments involving realistically low challenge doses require large numbers of animals has so far prevented the development of alternatives to using high challenge doses. METHODS AND
findingsUsing statistical power analysis, we investigate how many animals would be needed to conduct preclinical trials using low virus challenge doses. We show that experimental designs in which animals are repeatedly challenged with low doses do not require unfeasibly large numbers of animals to assess vaccine or microbicide success.
conclusionPreclinical trials using repeated low-dose challenges represent a promising alternative approach to identify potential preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.